These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7310392)

  • 61. [Clinical relevance of changes in serum prolactin level caused by electroconvulsive therapy].
    Gangadhar BN; Hofmann P; Karazman R; Probst C; Koinig G
    Wien Klin Wochenschr; 1996; 108(4):101-4. PubMed ID: 8867482
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of the effect of apomorphine and L-DOPA on serum growth hormone levels in normal men.
    Lal S; Martin JB; De la Vega CE; Friesen HG
    Clin Endocrinol (Oxf); 1975 May; 4(3):277-85. PubMed ID: 1149303
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immediate serum growth hormone decrease as a potential index of dopamine-related response to electroconvulsive therapy in schizophrenic patients.
    Pacitti F; Iannitelli A; Caredda M; Marconi D; Limpido L; Bersani G
    J ECT; 2011 Jun; 27(2):119-22. PubMed ID: 20562641
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of ECT on prolactin, LH, FSH and testosterone in males with major depressive illness.
    Cooper AJ; Finlayson R; Velamoor VR; Magnus RV; Cernovsky Z
    Can J Psychiatry; 1989 Nov; 34(8):814-7. PubMed ID: 2510920
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [TBL] [Abstract][Full Text] [Related]  

  • 66. ECT and Parkinson's disease revisited: a "naturalistic" study.
    Douyon R; Serby M; Klutchko B; Rotrosen J
    Am J Psychiatry; 1989 Nov; 146(11):1451-5. PubMed ID: 2817117
    [TBL] [Abstract][Full Text] [Related]  

  • 67. IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.
    Oertel WH; Schwarz J; Tatsch K; Arnold G; Gasser T; Kirsch CM
    Adv Neurol; 1993; 60():519-24. PubMed ID: 8420182
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hypothalamo-pituitary function and dopamine dependence in untreated parkinsonian patients.
    Cusimano G; Capriani C; Bonifati V; Meco G
    Acta Neurol Scand; 1991 Mar; 83(3):145-50. PubMed ID: 1903236
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Carbidopa inhibits the growth hormone- and prolactin-suppressive effect of L-dopa in acromegalic patients.
    Camanni F; Picotti GB; Massara F; Molinatti GM; Mantegazza P; Müller EE
    J Clin Endocrinol Metab; 1978 Sep; 47(3):647-52. PubMed ID: 263317
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
    Bell RD; Carruth A; Rosenberg RN; Boyar RM
    J Clin Endocrinol Metab; 1978 Oct; 47(4):807-11. PubMed ID: 45469
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment of Parkinson's disease with electroconvulsive therapy.
    Rasmussen K; Abrams R
    Psychiatr Clin North Am; 1991 Dec; 14(4):925-33. PubMed ID: 1771154
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Stereospecificity of the dopamine receptor mediating the growth hormone response to apomorphine in man. Short communication.
    Lal S; Nair NP; Thavundayil JX; Tawar V; Quirion R; Guyda H
    J Neural Transm Gen Sect; 1991; 85(2):157-64. PubMed ID: 1930878
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Responses of growth hormone and prolactin to L-Dopa in women with polycystic ovarian syndrome].
    Wu X; Gu Q; Su Y
    Zhonghua Fu Chan Ke Za Zhi; 1997 Aug; 32(8):489-91. PubMed ID: 9639745
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Electroconvulsive therapy (ECT) increases plasma growth hormone, prolactin, luteinising hormone and follicle-stimulating hormone but not thyrotropin or substance P.
    Skrabanek P; Balfe A; Webb M; Maguire J; Powell D
    Psychoneuroendocrinology; 1981; 6(3):261-7. PubMed ID: 6170084
    [No Abstract]   [Full Text] [Related]  

  • 75. Oestrogen-stimulated neurophysin and outcome after electroconvulsive therapy.
    Scott AI; Whalley LJ; Bennie J; Bowler G
    Lancet; 1986 Jun; 1(8495):1411-4. PubMed ID: 2872518
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
    Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
    Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of apomorphine and L-dopa on the parkinsonian bladder.
    Aranda B; Cramer P
    Neurourol Urodyn; 1993; 12(3):203-9. PubMed ID: 8330043
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
    Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of ECT on pituitary hormone release: relationship to seizure, clinical variables and outcome.
    Deakin JF; Ferrier IN; Crow TJ; Johnstone EC; Lawler P
    Br J Psychiatry; 1983 Dec; 143():618-24. PubMed ID: 6661605
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states.
    Verde G; Chiodini PG; Liuzzi A; Cozzi R; Favales F; Botalla L; Spelta B; Dalla Bonzana D; Rainer E; Horowski R
    J Endocrinol Invest; 1980; 3(4):405-14. PubMed ID: 6782153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.